Connect Biopharma Holdings (CNTB) Depreciation & Amortization (CF) (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted Depreciation & Amortization (CF) of $164000.0 for Q1 2026, down 9.39% sequentially from $181000.0 in Q4 2025, and down 5.2% YoY from $173000.0 in Q1 2025.
Connect Biopharma Holdings (CNTB) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Depreciation & Amortization (CF) for 3 years, with the latest figure at $164000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 5.2% year-over-year to $164000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $695000.0 (up 3.89% YoY) and the FY2025 annual result came in at $704000.0, up 6.67% from the prior year.
- Depreciation & Amortization (CF) eased to $164000.0 in Q1 2026 per CNTB's latest filing, from $181000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $181000.0 in Q4 2025 and troughed at $158000.0 in Q4 2024.
- A 3-year average of $169777.8 and a median of $171000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) rose 14.56% in 2025, then fell 5.2% in 2026.
- Over 3 years, Depreciation & Amortization (CF) stood at $158000.0 in 2024, then increased by 14.56% to $181000.0 in 2025, then slipped by 9.39% to $164000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $164000.0, $181000.0, and $179000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Connect Biopharma Holdings | 148.41 Mn | 148.41 Mn | - | 161,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 161,000.00 |
| Jun 30, 2026 | 161,000.00 |
| Mar 31, 2026 | 164,000.00 |
| Mar 31, 2026 | 164,000.00 |
| Dec 31, 2025 | 181,000.00 |
| Dec 31, 2025 | 181,000.00 |
| Sep 30, 2025 | 179,000.00 |
| Sep 30, 2025 | 179,000.00 |
| Jun 30, 2025 | 171,000.00 |
| Jun 30, 2025 | 171,000.00 |
| Mar 31, 2025 | 173,000.00 |
| Mar 31, 2025 | 173,000.00 |
| Dec 31, 2024 | 158,000.00 |
| Dec 31, 2024 | 158,000.00 |
| Sep 30, 2024 | 176,000.00 |
| Sep 30, 2024 | 176,000.00 |
| Jun 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 162,000.00 |
| Mar 31, 2024 | 164,000.00 |
| Mar 31, 2024 | 164,000.00 |